IL6 and myeloid sarcoma: It can therefore be assumed that among patients with IR, an increased tendency to develop urolithiasis can be expected and vice versa, due to similar mechanisms causing these diseases, such as the presence of systemic metabolic acidosis, MS features, and the presence of inflammatory mediators such as interleukin 6 (IL-6) or tumor necrosis alpha (TNFα).